Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Exclusion Criteria

• •History of hemiplegic migraine, cluster headache, or other trigeminal autonomic cephalalgia.
• •Has any medical contraindication to the use of an oral triptan.
• •Previously treated with erenumab.
• •Previously treated with a gepant (small molecule calcitonin gene related peptide receptor \[CGRP-R\] antagonist) in a preventive fashion in a manner consistent with migraine prevention that either:
• •1. In the opinion of the investigator, did not offer any evidence of a therapeutic response or
• •2. Was discontinued for less than 12 weeks from the date of initial screening or
• •3. Was previously discontinued due to a known adverse drug reaction
• •Currently being treated with lasmiditan and/or a gepant in the acute setting.
• •No therapeutic response with greater than 4 of the defined medication categories after an adequate therapeutic trial.
• •Currently has a history of consistent excellent response to oral triptans, defined as achievement of pain-freedom in ≤ 1 hour for ≥ 50% of treated attacks of at least moderate pain intensity during the 3 months prior to screening.
• •Use of triptans administered via a non-oral (e.g. subcutaneous \[SC\] or intranasal delivery systems) or sublingual route at the time of screening, during the run-in and baseline periods, and throughout the study duration.